Abstract
Novel artemisinin-glycolipid hybrids were directly synthesized from 12β (C-C)-type deoxoartemisinin and glycolipid and exhibited exceptional in vitro anticancer activity, particularly against the oral carcinoma cancer cell lines, respectively. The artemisinin-glycolipid hybrids, with effective concentrations under 20μM, demonstrated better anticancer activity than either artemisinin or glycolipid alone and showed five times more anti-oral cancer activity than either cisplatin or paclitaxel.
| Original language | English |
|---|---|
| Pages (from-to) | 1471-1475 |
| Number of pages | 5 |
| Journal | Chemical and Pharmaceutical Bulletin |
| Volume | 59 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2011 Dec 12 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Chemistry(all)
- Drug Discovery
Cite this
}
Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents. / Ricci, Jérémy; Kim, Minkyu; Chung, Won Yoon; Park, Kwang Kyun; Jung, Mankil.
In: Chemical and Pharmaceutical Bulletin, Vol. 59, No. 12, 12.12.2011, p. 1471-1475.Research output: Contribution to journal › Article
TY - JOUR
T1 - Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents
AU - Ricci, Jérémy
AU - Kim, Minkyu
AU - Chung, Won Yoon
AU - Park, Kwang Kyun
AU - Jung, Mankil
PY - 2011/12/12
Y1 - 2011/12/12
N2 - Novel artemisinin-glycolipid hybrids were directly synthesized from 12β (C-C)-type deoxoartemisinin and glycolipid and exhibited exceptional in vitro anticancer activity, particularly against the oral carcinoma cancer cell lines, respectively. The artemisinin-glycolipid hybrids, with effective concentrations under 20μM, demonstrated better anticancer activity than either artemisinin or glycolipid alone and showed five times more anti-oral cancer activity than either cisplatin or paclitaxel.
AB - Novel artemisinin-glycolipid hybrids were directly synthesized from 12β (C-C)-type deoxoartemisinin and glycolipid and exhibited exceptional in vitro anticancer activity, particularly against the oral carcinoma cancer cell lines, respectively. The artemisinin-glycolipid hybrids, with effective concentrations under 20μM, demonstrated better anticancer activity than either artemisinin or glycolipid alone and showed five times more anti-oral cancer activity than either cisplatin or paclitaxel.
UR - http://www.scopus.com/inward/record.url?scp=82955249853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955249853&partnerID=8YFLogxK
U2 - 10.1248/cpb.59.1471
DO - 10.1248/cpb.59.1471
M3 - Article
C2 - 22130368
AN - SCOPUS:82955249853
VL - 59
SP - 1471
EP - 1475
JO - Chemical and Pharmaceutical Bulletin
JF - Chemical and Pharmaceutical Bulletin
SN - 0009-2363
IS - 12
ER -